NanoViricides, Stock

NanoViricides, Current Liabilities

The Current Liabilities of NanoViricides, (NNVC) as of Aug 12, 2026 is 1.33 M USD. In the previous year, Current Liabilities was 1.62 M USD — a change of -17.81% (lower).

Current Liabilities

1.33 MUSD

YoY

-17.81%

Last updated:

Current Liabilities of NanoViricides, is 2026 1.33 M USD. Current Liabilities of NanoViricides, was 2025 1.62 M USD. It decreases by -17.81% lower compared to the previous year.
Access this data via the Eulerpool API

NanoViricides, Stock analysis

What does NanoViricides, do? NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of virus infections. The company's unique technology is based on nanoparticles that specifically target and destroy virus cells. The company was founded in 2005 by Farooq Ansari, a former top manager at Pfizer. Together with his team, he quickly recognized the potential of nanotechnology in combating diseases and began developing various products based on this technology. NanoViricides Inc.'s business model is based on the development and commercialization of nanoparticle-based therapeutics in the global health market. The company works closely with leading research and development institutions to expand knowledge and technology in this field. NanoViricides Inc. has several product divisions specializing in combating different virus infections. The main divisions are: - FluCide: Focuses on the development of therapeutics for the treatment of influenza infections. Flu is one of the most widespread virus infections worldwide and can lead to serious complications such as pneumonia. - HerpeCide: Focuses on the development of therapeutics for the treatment of herpesvirus infections, including genital herpes, shingles, and chickenpox. - HIVCide: Focuses on the development of therapeutics for the treatment of HIV infections, aiming to develop a safer and more effective cure for HIV. - RabiCide: Focuses on the development of therapeutics for the treatment of rabies infections. - CoronaCide: Focuses on the development of therapeutics for the treatment of coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. NanoViricides Inc. has a range of products in various stages of development and research, with some already in clinical studies. The company continuously strives to improve its products and expand its research and development efforts. In summary, NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of virus infections. It utilizes a unique technology based on nanoparticles to directly combat viruses at the cellular level. With multiple product divisions and a strong team of researchers and developers, NanoViricides Inc. is continuously working to improve the health of patients worldwide. The answer is: NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for virus infections using nanoparticle-based technology. NanoViricides, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NanoViricides, stock

Current Liabilities of NanoViricides, is 1.33 M USD in 2026.

Current Liabilities of NanoViricides, changed from 1.62 M USD to 1.33 M USD, representing a -17.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities NanoViricides, since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's NanoViricides, historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — NanoViricides,

All Key Metrics — NanoViricides,